MetaCap

Cardiol Therapeutics (CRDL) vs Humacyte (HUMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed Humacyte (HUMA) over the past year, losing 11.3% versus a loss of 63.5%. Over five years, CRDL leads with a -60.1% price change compared with -95.9% for HUMA. Humacyte is the larger company by market cap ($123.7 million vs $110.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%HUMA-63.49%
+145%+32%-81%
Nov 21, 20251 yearNov 20, 2026
CRDL-57.92%HUMA-95.93%
+34%-34%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus HUMA key metrics
MetricCRDLHUMA
Share price$0.8626$0.4454
Market cap$110.14M$123.73M
1-day change-2.28%-17.90%
YTD return-9.58%-53.65%
1-year return-11.35%-63.49%
5-year return-60.06%-95.94%
EPS (TTM)$-0.24$-0.45
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.04M
Net income (latest FY)—$-40.83M
Gross margin—-376.05%
Operating margin—-5306.04%
Net margin—-2003.58%
52-week high$2.34$1.53
52-week low$0.8417$0.337
Distance from 52-week high-63.14%-70.79%
Analyst consensusstrong_buybuy
Avg. price target upside+874.96%+268.21%
Average volume1.20M5.36M
Shares outstanding127.69M277.80M
Employees18184
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed HUMA by 52.1 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About Humacyte

HUMA stock →

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees

CRDL vs HUMA FAQ

Which is bigger, Cardiol Therapeutics or Humacyte?

Humacyte (HUMA) is larger, with a market capitalization of $123.73M compared with $110.14M for Cardiol Therapeutics (CRDL).

Which stock has performed better over the past year, CRDL or HUMA?

CRDL returned -11.35% over the past 12 months, compared with -63.49% for HUMA (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and Humacyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons